Novel Inhibitor of Hematopoietic Cell Kinase as a Potential Therapeutic Agent for Acute Myeloid Leukemia

Scientists investigated in vitro, ex vivo and in vivo effects of a novel chemical compound targeting HCK inhibition, in combination with the most used drugs for the treatment of myelodysplastic syndrome and de novo acute myeloid leukemia, 5-Azacytidine and Cytarabine.